351 related articles for article (PubMed ID: 23259070)
1. The Interface between BCR-ABL-Dependent and -Independent Resistance Signaling Pathways in Chronic Myeloid Leukemia.
Nestal de Moraes G; Souza PS; Costas FC; Vasconcelos FC; Reis FR; Maia RC
Leuk Res Treatment; 2012; 2012():671702. PubMed ID: 23259070
[TBL] [Abstract][Full Text] [Related]
2. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.
Ali MA
Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498
[TBL] [Abstract][Full Text] [Related]
3. Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells.
Lernoux M; Schnekenburger M; Losson H; Vermeulen K; Hahn H; Gérard D; Lee JY; Mazumder A; Ahamed M; Christov C; Kim DW; Dicato M; Bormans G; Han BW; Diederich M
Clin Epigenetics; 2020 May; 12(1):69. PubMed ID: 32430012
[TBL] [Abstract][Full Text] [Related]
4. Role of anti-apoptotic pathways activated by BCR/ABL in the resistance of chronic myeloid leukemia cells to tyrosine kinase inhibitors.
Danisz K; Blasiak J
Acta Biochim Pol; 2013; 60(4):503-14. PubMed ID: 24273759
[TBL] [Abstract][Full Text] [Related]
5. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
An X; Tiwari AK; Sun Y; Ding PR; Ashby CR; Chen ZS
Leuk Res; 2010 Oct; 34(10):1255-68. PubMed ID: 20537386
[TBL] [Abstract][Full Text] [Related]
6. Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.
Hekmatshoar Y; Ozkan T; Altinok Gunes B; Bozkurt S; Karadag A; Karabay AZ; Sunguroglu A
Cell Mol Biol (Noisy-le-grand); 2018 May; 64(6):23-30. PubMed ID: 29808796
[TBL] [Abstract][Full Text] [Related]
7. Bone marrow-derived mesenchymal stromal cells promote resistance to tyrosine kinase inhibitors in chronic myeloid leukemia via the IL-7/JAK1/STAT5 pathway.
Zhang X; Tu H; Yang Y; Jiang X; Hu X; Luo Q; Li J
J Biol Chem; 2019 Aug; 294(32):12167-12179. PubMed ID: 31235520
[TBL] [Abstract][Full Text] [Related]
8. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
9. Cumulative clinical experience from a decade of use: imatinib as first-line treatment of chronic myeloid leukemia.
Baran Y; Saydam G
J Blood Med; 2012; 3():139-50. PubMed ID: 23180974
[TBL] [Abstract][Full Text] [Related]
10. New Developments in Chronic Myeloid Leukemia: Implications for Therapy.
Tabarestani S; Movafagh A
Iran J Cancer Prev; 2016 Feb; 9(1):e3961. PubMed ID: 27366312
[TBL] [Abstract][Full Text] [Related]
11. Chronic Myeloid Leukemia (CML) Mouse Model in Translational Research.
Peng C; Li S
Methods Mol Biol; 2016; 1438():225-43. PubMed ID: 27150093
[TBL] [Abstract][Full Text] [Related]
12. Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia.
Li S
Leuk Lymphoma; 2008 Jan; 49(1):19-26. PubMed ID: 18203007
[TBL] [Abstract][Full Text] [Related]
13. Chronic Myeloid Leukemia: Existing Therapeutic Options and Strategies to Overcome Drug Resistance.
Singh VK; Coumar MS
Mini Rev Med Chem; 2019; 19(4):333-345. PubMed ID: 30332954
[TBL] [Abstract][Full Text] [Related]
14. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
Walz C; Sattler M
Crit Rev Oncol Hematol; 2006 Feb; 57(2):145-64. PubMed ID: 16213151
[TBL] [Abstract][Full Text] [Related]
15. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
[TBL] [Abstract][Full Text] [Related]
16. Combating TKI resistance in CML by inhibiting the PI3K/Akt/mTOR pathway in combination with TKIs: a review.
Singh P; Kumar V; Gupta SK; Kumari G; Verma M
Med Oncol; 2021 Jan; 38(1):10. PubMed ID: 33452624
[TBL] [Abstract][Full Text] [Related]
17. [MET/ERK and MET/JNK Pathway Activation Is Involved in BCR-ABL Inhibitor-resistance in Chronic Myeloid Leukemia].
Tsubaki M
Yakugaku Zasshi; 2018; 138(12):1461-1466. PubMed ID: 30504658
[TBL] [Abstract][Full Text] [Related]
18. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
19. Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms.
Lan X; Zhao C; Chen X; Zhang P; Zang D; Wu J; Chen J; Long H; Yang L; Huang H; Carter BZ; Wang X; Shi X; Liu J
J Hematol Oncol; 2016 Nov; 9(1):129. PubMed ID: 27884201
[TBL] [Abstract][Full Text] [Related]
20. USP10 modulates the SKP2/Bcr-Abl axis via stabilizing SKP2 in chronic myeloid leukemia.
Liao Y; Liu N; Xia X; Guo Z; Li Y; Jiang L; Zhou R; Tang D; Huang H; Liu J
Cell Discov; 2019; 5():24. PubMed ID: 31044085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]